The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...

Subscribe for FREE Mice without the SCN1B gene experience seizures and 100 percent mortality just three weeks after birth. Using mouse models, the investigative team, led by Chunling Chen, M.D., and ...

Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy.

The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with drug-resistant mesial temporal lobe epilepsy SAN FRANCISCO, Feb.

Epilepsy in children can be a challenging condition to manage. Here's a comprehensive overview of the causes, dietary ...

In the evolving landscape of medical advancements, focused ultrasound has emerged as a groundbreaking, non-invasive therapy ...

Administering the therapy to newborn mice increased their survival, reduced the severity of their seizures and restored brain neuron excitability. The team notes that different forms of SCN1B gene ...

Epilepsy is a neurological disorder that disrupts nerve cell activity in the brain yet a normal life can be led with therapy ...

The potential new idiopathic epilepsy therapy has been developed utilizing Chou2 Pharma's unique precision cannabinoid formulating platform. "We are extremely excited to be working with Dr.